In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT(1A) Receptor Agonist for the Treatment of Schizophrenia

PURPOSE: Ulotaront (SEP-363856) is a TAAR1 agonist with 5-HT(1A) agonist activity currently in clinical development for the treatment of schizophrenia. The objectives of the current study were to characterize the in vitro ADME properties, preclinical PK, and to evaluate the DDI potential of ulotaron...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Guangqing, Chen, Yu-Luan, Dedic, Nina, Xie, Linghong, Koblan, Kenneth S., Galluppi, Gerald R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160101/
https://www.ncbi.nlm.nih.gov/pubmed/35484370
http://dx.doi.org/10.1007/s11095-022-03267-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160101/
https://www.ncbi.nlm.nih.gov/pubmed/35484370
http://dx.doi.org/10.1007/s11095-022-03267-1

Ejemplares similares